Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Reports Decline in Cash Receipts for Fiscal Q2

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies today reported a 41 percent drop in cash receipts from customers in its fiscal second quarter compared with the previous quarter.

For the three-month period ended Dec. 31, Genetic Technologies' cash receipts fell to A$106,000 (US$85,765) from A$179,000 in fiscal Q1. Meanwhile, the company reported a 55 percent year-over-year drop in test samples received to 125 from 278. In the fiscal first quarter, the company received 115 test samples.

Genetic Technologies' operational cash spend in the fiscal second quarter was A$1.3 million versus A$2.3 million in the previous quarter, and the company said it expects to spend A$1.6 million in the current quarter. For the full fiscal year 2018, it anticipates a cash spend of A$6.6 million, a 15 percent reduction from fiscal 2017.

At the end of 2017, Genetic Technologies held A$7.6 million in cash.

During the quarter, Genetic Technologies was notified that it will be required to convene a shareholder meeting at the request of a group of shareholders seeking the removal of three executive directors including CEO Eutillio Buccilli. The company said today that it is recommending its shareholders vote against the resolutions being presented at the meeting, which will be held on Wednesday.

The shareholder meeting comes as Genetic Technologies' conducts an ongoing review of strategic alternatives.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.